Edition:
United States

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

17.78CHF
10:34am EST
Change (% chg)

CHF-0.77 (-4.15%)
Prev Close
CHF18.55
Open
CHF18.49
Day's High
CHF18.79
Day's Low
CHF17.75
Volume
189,581
Avg. Vol
284,758
52-wk High
CHF30.70
52-wk Low
CHF17.75

Select another date:

Mon, Nov 5 2018

BRIEF-Idorsia Maintains Collaboration Agreement With Reveragen

* FOLLOWING RECEIPT OF CLINICAL STUDY REPORT FOR PHASE 2A STUDY WITH VAMOROLONE, WILL PAY REVERAGEN USD 15 MILLION TO MAINTAIN AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia Says Representative Of Former Axovan Shareholders Filed Complaint Against Actelion

* SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS CLAIMS DEMERGER OF ACTELION AND IDORSIA WOULD TRIGGER ACCELERATION OF ALL OUTSTANDING MILESTONE PAYMENTS FOR CLAZOSENTAN

BRIEF-Idorsia 9Mth US GAAP Net Loss Of CHF 278 Mln

* US GAAP OPERATING RESULTS IN 9M 2018: LOSS OF CHF 271 MILLION

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 159 Mln

* US GAAP OPERATING RESULTS IN HY 2018: LOSS OF CHF 155 MILLION

UPDATE 1-Idorsia CEO accelerates fundraising with 505 mln Sfr deal

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline

ZURICH, July 11 Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

BRIEF-Idorsia Launches Offering Of New Shares And Convertible Bonds

* IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE

After split from Actelion, Idorsia CEO plans to raise more cash in 2019

ALLSCHWIL, Switzerland Swiss biotech Idorsia , spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson , will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters.

BRIEF-Idorsia Initiates Phase 3 Registration Program With Nemorexant For Treatment Of Insomnia

* INITIATES A PHASE 3 REGISTRATION PROGRAM WITH NEMOREXANT (ACT-541468) FOR TREATMENT OF INSOMNIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: